Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.77 USD
Change Today +0.01 / 1.32%
Volume 98.5K
ABIO On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

arca biopharma inc (ABIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $1.65
52 Week Low
02/11/15 - $0.65
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARCA BIOPHARMA INC (ABIO)

Related News

No related news articles were found.

arca biopharma inc (ABIO) Related Businessweek News

No Related Businessweek News Found

arca biopharma inc (ABIO) Details

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. The company has a collaboration agreement with Medtronic, Inc. for the support of Gencaro’s Phase IIB/III clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

16 Employees
Last Reported Date: 03/19/15

arca biopharma inc (ABIO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $300.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $285.6K
Compensation as of Fiscal Year 2014.

arca biopharma inc (ABIO) Key Developments

ARCA biopharma, Inc. Proposes Amendments to the Restated Certificate of Incorporation

ARCA biopharma, Inc. proposed to approve amendments to the Company’s restated certificate of incorporation, as amended, and authorize the Board of Directors, if in their judgment it is necessary, to select and file one such amendment to effect a reverse stock split of common stock, at a ratio in the range of 3:1 to 20:1, such ratio to be determined at the discretion of the Board of Directors, to it's annual general meeting to be held on June 04, 2015.

ARCA biopharma, Inc. Announces Investigation of Gencaro for the Prevention of Atrial Fibrillation/Atrial Flutter by U.S. Food and Drug Administration (FDA)

ARCA biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Gencaro for the prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population (heart failure patients with reduced left ventricular ejection fraction, HFREF). Gencaro is the company's investigational, pharmacologically unique beta-blocker and mild vasodilator. According to the FDA's Fast Track Guidance document, Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Gencaro is currently being evaluated as a potential treatment for atrial fibrillation in a genetically-defined heart failure (HFREF) population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial. ARCA anticipates that enrollment of approximately 200 patients in the Phase 2B portion of the trial will be completed by the end of 2016.

ARCA biopharma, Inc. Auditor Raises 'Going Concern' Doubt

ARCA biopharma, Inc. filed its 10-K on Mar 19, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABIO:US $0.77 USD +0.01

ABIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation ABIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARCA BIOPHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at